Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study

被引：1

作者：

Pils, Marlene ^{[1
,2
]}

Dybala, Alexandra ^{[3
]}

Schaffrath, Anja ^{[1
]}

Rehn, Fabian ^{[1
,2
]}

Kutzsche, Janine ^{[1
]}

Bloemeke, Lara ^{[1
]}

Tusche, Markus ^{[1
]}

Oezduezenciler, Pelin ^{[1
]}

Bujnicki, Tuyen ^{[1
]}

Kraemer-Schulien, Victoria ^{[1
]}

Gramespacher, Hannes ^{[4
]}

Schmieschek, Maximilian H. T. ^{[4
]}

Barbe, Michael T. ^{[4
]}

Onur, Oezguer A. ^{[4
,5
]}

Fink, Gereon R. ^{[4
,5
]}

Tamguney, Gultekin ^{[1
,3
]}

Bannach, Oliver ^{[1
,2
]}

Willbold, Dieter ^{[1
,2
,3
]}

机构：

[1] Forschungszentrum Julich, Inst Biol Informat Proc, Struct Biochem IBI 7, D-52428 Julich, Germany

[2] attyloid GmbH, D-40225 Dusseldorf, Germany

[3] Heinrich Heine Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany

[4] Univ Cologne, Univ Hosp Cologne, Fac Med, Dept Neurol, D-50937 Cologne, Germany

[5] Res Ctr Julich, Inst Neurosci & Med INM 3, Cognit Neurosci, D-52428 Julich, Germany

来源：

ALZHEIMERS RESEARCH & THERAPY | 2024年 / 16卷 / 01期

关键词：

Amyloidosis; A beta oligomer quantitation; sFIDA; Brain-gut-microbiota axis; Leaky gut; Fecal/stool samples; Clearance; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; GUT-MICROBIOTA; DIAGNOSIS; BRAIN;

D O I：

10.1186/s13195-024-01597-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

BackgroundMisfolding and aggregation of amyloid beta (A beta), along with neurofibrillary tangles consisting of aggregated Tau species, are pathological hallmarks of Alzheimer's disease (AD) onset and progression. In this study, we hypothesized the clearance of A beta aggregates from the brain and body into the gut.MethodsTo investigate this, we used surface-based fluorescence intensity distribution analysis (sFIDA) to determine the A beta aggregate concentrations in feces from 26 AD patients and 31 healthy controls (HC).ResultsA beta aggregates were detectable in human feces and their concentrations were elevated in AD patients compared to HC (specificity 90.3%, sensitivity 53.8%).ConclusionThus, fecal A beta aggregates constitute a non-invasive biomarker candidate for diagnosing AD. Whether digestion-resistant A beta aggregates in feces are secreted via the liver and bile or directly from the enteric neuronal system remains to be elucidated.

引用

页数：15

共 50 条

[11] Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study
Decourt, Boris
Walker, Aaron
Gonzales, Amanda
Malek-Ahmadi, Michael
Liesback, Carolyn
Davis, Kathryn J.
Belden, Christine M.
Jacobson, Sandra A.
Sabbagh, Marwan N.
PLATELETS, 2013, 24 (03) : 235 - 238
[12] Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration
Swerdlow, Neal R.
Kotz, Juliana E.
Joshi, Yash B.
Talledo, Jo
Sprock, Joyce
Molina, Juan L.
Huisa, Branko
Huege, Steven F.
Romero, Jairo Alberto
Walsh, Michael J.
Delano-Wood, Lisa
Light, Gregory A.
JOURNAL OF ALZHEIMERS DISEASE, 2021, 84 (04) : 1431 - 1438
[13] Sleep parameters assessed by actigraphy in Fabry's disease patients: a proof-of-concept
da Silva Vallim, Julia Ribeiro
do Amaral, Fernanda Gaspar
D'Almeida, Vania
SLEEP MEDICINE, 2020, 69 : 213 - 216
[14] Quantitative Measurements of Motor Function in Alzheimer's Disease, Frontotemporal Dementia, and Dementia with Lewy Bodies: A Proof-of-Concept Study
Kragh, Frederikke Jeppesen
Bruun, Marie
Budtz-Jorgensen, Esben
Hjermind, Lena Elisabeth
Schubert, Robin
Reilmann, Ralf
Nielsen, Jorgen Erik
Hasselbalch, Steen Gregers
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2018, 46 (3-4) : 168 - 179
[15] Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study
Safarpour, Delaram
Brumbach, Barbara H.
Arena, Monica
Quinn, Joseph
Diamond, Sarah
Nutt, Jay G.
Pfeiffer, RonaldF.
MOVEMENT DISORDERS, 2022, 37 (10) : 2153 - 2158
[16] Elephants, Parkinson's Disease, and Proof-of-Concept Clinical Trials
Cedarbaum, Jesse M.
MOVEMENT DISORDERS, 2018, 33 (05) : 697 - 700
[17] Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof-of-concept study
D'Haens, G.
Danese, S.
Davies, M.
Watanabe, M.
Hibi, T.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S55 - S56
[18] Preclinical Biomarkers of Alzheimer's Disease Neuropathology in Young Adults with Youth-Onset Diabetes (YDM)-A Proof-of-Concept Study
Shapiro, Allison
Coughlan, Christina
Kim, Jeongchul
Potter, Huntington
Bjornstad, Petter
Pauley, Meghan E.
Rajic, Benjamin S.
Truong, Jennifer
Glueck, Deborah H.
Harrall, Kylie K.
Barcus, Richard A.
Tan, Josh
Bettcher, Brianne
Thaker, Ashesh
Walker, Keenan A.
Liese, Angela D.
Dabelea, Dana
Whitlow, Christopher T.
DIABETES, 2023, 72
[19] Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study
So Hee Park
Kyoungwon Baik
Seun Jeon
Won Seok Chang
Byoung Seok Ye
Jin Woo Chang
Translational Neurodegeneration, 10
[20] Nucleoside Reverse Transcriptase Inhibitor Exposure Is Associated with Lower Alzheimer's Disease Risk: A Retrospective Cohort Proof-of-Concept Study
Chow, Tiffany W.
Raupp, Mark
Reynolds, Matthew W.
Li, Siying
Kaeser, Gwendolyn E.
Chun, Jerold
PHARMACEUTICALS, 2024, 17 (04)

← 1 2 3 4 5 →